FDA Proposes Revised Software Guidance to Clarify Clinical Decision Support Tools

The FDA released updated draft guidance in April 2024 that refines how software functions in wellness devices are assessed for regulatory oversight. The changes build on earlier policies by offering more examples of intended uses that stay outside device rules and those that cross into regulated territory. Public comment remains open on the drafts.

Current Policy on Wellness Software

The agency maintains that software aimed only at general wellness goals, such as supporting healthy habits, usually falls outside FDA device regulation. This holds when the software avoids claims tied to diagnosing, treating, or preventing specific diseases or conditions. Earlier guidance from the same year already outlined this boundary.

FDA's decision flowchart clarifying when software functions fall outside or within device regulation under the updated 2024 draft guidance.

Examples of Regulated and Non-Regulated Functions

New sections in the draft list concrete scenarios. Health trackers that prompt exercise or sleep improvements without referencing medical conditions stay exempt. In contrast, software that claims to evaluate risk for a diagnosed condition or interpret clinical data may trigger oversight. These distinctions appear across the two primary guidance documents.

Added Focus on Security and Compatibility

The updates also highlight cybersecurity, labeling, and data exchange needs for digital health products. Manufacturers receive clearer signals on addressing these elements during design. The Digital Health Center of Excellence page summarizes these points as part of ongoing policy evolution.

What this means

The draft documents reduce uncertainty for developers by spelling out risk thresholds and use cases in greater detail. They keep the core distinction between low-risk wellness tools and functions that meet device criteria. Implementation details will depend on final versions after comments close.

Key takeaways

• Software limited to lifestyle promotion without disease references remains outside FDA device rules, per the 2024 general wellness guidance [1].
• Expanded examples show trackers focused on healthy routines avoid regulation while tools claiming diagnostic functions do not [2].
• Cybersecurity and interoperability receive explicit attention in the latest policy navigator updates [3].
• The documents are drafts open to comment, so final language and timelines are not yet fixed.
• State and international rules fall outside the scope of these federal updates.

Limitations

These materials represent draft guidance still subject to public input. Regulatory interpretations could shift once feedback is incorporated, and no firm dates for final versions have been set. The documents do not cover state-level or international requirements.

Last updated: September 3, 2026